1,416 reports of this reaction
0.9% of all ERENUMAB AOOE reports
#20 most reported adverse reaction
HYPOAESTHESIA is the #20 most commonly reported adverse reaction for ERENUMAB AOOE, manufactured by Amgen Inc. There are 1,416 FDA adverse event reports linking ERENUMAB AOOE to HYPOAESTHESIA. This represents approximately 0.9% of all 151,566 adverse event reports for this drug.
Patients taking ERENUMAB AOOE who experience hypoaesthesia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPOAESTHESIA is a less commonly reported adverse event for ERENUMAB AOOE, but still significant enough to appear in the safety profile.
In addition to hypoaesthesia, the following adverse reactions have been reported for ERENUMAB AOOE:
The following drugs have also been linked to hypoaesthesia in FDA adverse event reports:
HYPOAESTHESIA has been reported as an adverse event in 1,416 FDA reports for ERENUMAB AOOE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPOAESTHESIA accounts for approximately 0.9% of all adverse event reports for ERENUMAB AOOE, making it a notable side effect.
If you experience hypoaesthesia while taking ERENUMAB AOOE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.